4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer

Conditions:Breast Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:50 - Any
Start Date:January 10, 2012
End Date:July 17, 2017

Use our guide to learn which trials are right for you!

A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In The Treatment Of Stage 0 and l Breast Cancer

The Purpose of this study is to evaluate the feasibility of using image guidance and
four-dimensional computed tomography to reduce the volume of non target breast tissue that is
treated with accelerated partial breast irradiation via the external beam technique.

This is a pilot study enrolling about 30 patients to evaluate the feasibility of using 4D CT
and daily image guidance in Accelerated Partial Breast Irradiation (APBI) to decrease set-up
error and individualized planning target volumes to limit the non-target breast tissue dose.
The two specific breasts constraints which shall be decreased are the V50 (percent volume of
breast receiving 50% of the prescribed dose) and the V100 (percent volume of breast receiving
100% of the prescribed dose). The goal will be to decrease these to 45% and 23.5%
respectively, which is down 33% from the NSABP B39 standard of 60% and 35%.

Inclusion Criteria:

- The patient must consent to be in the study and must have a signed an approved consent
form conforming with institutional guidelines.

- Patient must be > 50 years old.

- The patient should have a life expectancy of at least two years with a karnofsky
performance status > 70.

- The patient must have stage 0 or I breast cancer.

- On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the

- Surgical treatment of the breast must have been lumpectomy. The margins of the
resected specimen must be histologically free of tumor (>2mm, DCIS and invasive).
Re-excision of surgical margins is permitted.

- Gross disease must be unifocal with pathologic (invasive and/or DCIS) tumor size 2 cm
or less. (Patients with microscopic multifocality are eligible as long as total
pathologic tumor size is 2 cm or less.)

- Patients with invasive breast cancer are required to have axillary staging which can
include sentinel node biopsy alone (if negative), sentinel node biopsy followed by
axillary dissection or sampling with a minimum total of 6 axillary nodes or axillary
dissection alone (with a minimum of 6 axillary nodes). Axillary staging is NOT
required for patients with DCIS.

- The patient must have simulation within 8 weeks/56 days of the final surgery for their
breast cancer (lumpectomy, re-excision of margins, or axillary staging procedure).

- Patients with a history of non-ipsilateral breast malignancies are eligible if they
have been disease-free for 2 or more years prior to enrollment. Patients with the
following cancers are eligible even if diagnosed and treated within the past 2 years:
carcinoma in situ of the cervix, colon, melanoma in situ, and basal cell and squamous
cell carcinoma of the skin.

- Chemotherapy is permitted if planned for ≥ 2 weeks after radiation.

- Urine pregnancy test must be performed and be negative on all women younger than 60
who have not had a tubal ligation, oophorectomy, or hysterectomy.

- Separate incisions for the lumpectomy and sentinel node biopsy should be present. Use
of only one incision will typically result in a contiguous cavity with the tumor bed
and the sentinel node sampling, and inability of the radiation oncologist to delineate
the tumor bed from the sentinel node bed.

- The patient must have a cavity which is able to be targeted with external beam APBI,
either through surgical clip placement, or CVS 3 or higher. The cavity to whole breast
ratio must be 30% or less.

Exclusion Criteria:

- Men are not eligible for this study as men are not breast conservation candidates.

- T0, T2 (> 2.0 cm), T3, node positive, stage III or IV breast cancer.

- Any positive axillary nodes.

- Palpable or radiographically suspicious ipsilateral or contralateral axillary,
supraclavicular, infraclavicular or internal mammary nodes, unless biopsy proven to be
negative for tumor.

- Suspicious microcalcifications, densities or palpable abnormalities in either breast
unless biopsy proven to be benign.

- Non-epithelial breast malignancies such as sarcoma or lymphoma.

- Proven multicentric carcinoma in more than one quadrant or separated by more than 2

- Paget's disease of the nipple.

- History of invasive breast cancer or DCIS in the same breast.

- Surgical margins that cannot be microscopically assessed or are less then 2 mm.

- Collagen vascular disease, specifically dermatomyositis with a CPK level above normal
or with an active skin rash, systemic lupus erythematosis or scleroderma.

- Pregnancy or lactation at the time of proposed radiation. Women of reproductive
potential must agree to use an effective non-hormonal method of contraception during

- Psychiatric or addictive disorders or other conditions that, in the opinion of the
treating physician, would preclude the patient from meeting the study requirements.

- Patients with coexisting medical conditions in whom life expectancy is < 2 years.

- Patients with skin involvement, regardless of tumor size.
We found this trial at
35 Park Street
New Haven, Connecticut 06510
New Haven, CT
Click here to add this to my saved trials